Anti-VEGF antibody constructs
US12365726B2 · kind B2 · utility
0Cited by
58References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 13, 2023 |
| Grant date | Jul 22, 2025 |
| Priority date | — |
| Expiry date | Apr 13, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.